中国P站

Obesity; Metabolic Syndrome; Insulin Resistance; Gut Microbiota; Adipose Tissue; Skeletal Muscle; Inflammation; Epigenetics; Genetics; Dietary Interventions; Exercise; Pharmacotherapy; Bariatric Surgery

Introduction

The development of obesity and metabolic syndrome is a multifaceted health challenge, driven by a complex interplay of biological systems and environmental factors. Current research offers deep insights into various contributing mechanisms and potential therapeutic avenues. This review delves into the complex interplay between gut microbiota and the development of obesity and metabolic syndrome. It highlights how microbial dysbiosis affects nutrient absorption, energy metabolism, inflammation, and hormone signaling, ultimately influencing weight gain and insulin resistance. Potential therapeutic targets include dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation [1].

This review explores the critical role of skeletal muscle lipid metabolism in developing insulin resistance in obesity and type 2 diabetes. Accumulation of intramyocellular lipids interferes with insulin signaling, leading to impaired glucose uptake. Contributing factors include mitochondrial dysfunction and altered fatty acid transport, suggesting therapeutic strategies targeting muscle lipid homeostasis [2].

This review focuses on adipose tissue dysfunction's crucial role in driving insulin resistance in obese individuals. Impaired adipocyte function, characterized by hypertrophy, chronic inflammation, and altered adipokine secretion, contributes significantly to systemic metabolic derangements. Understanding these pathways is key to developing targeted interventions for obesity-related complications [3].

This review synthesizes current understanding of how exercise influences obesity and metabolic health. Physical activity improves body composition, insulin sensitivity, lipid profiles, and reduces systemic inflammation. Both aerobic and resistance training have distinct and synergistic roles in mitigating metabolic consequences, advocating for tailored exercise prescriptions in obesity management [4].

This comprehensive review evaluates the long-term impact of bariatric surgery on metabolic health, highlighting sustained improvements in weight loss, glycemic control, and resolution of comorbidities. Mechanisms include hormonal changes, gut microbiota modulation, and altered nutrient sensing. These profoundly benefit metabolic health, alongside addressing potential challenges and nutritional considerations post-surgery [5].

This review updates on epigenetic mechanisms in obesity and metabolic syndrome. DNA methylation, histone modifications, and non-coding RNAs regulate gene expression in metabolic tissues, influencing adipogenesis and insulin sensitivity. Environmental factors induce epigenetic changes predisposing individuals to dysfunction, offering insights into potential epigenetic therapeutic targets and preventive strategies [6].

This narrative review examines recent evidence on dietary patterns' impact on metabolic health, particularly in obesity. It discusses benefits of Mediterranean, DASH, and plant-based diets in improving insulin sensitivity and reducing inflammation. Emphasizing whole foods, fiber, and healthy fats, while cautioning against processed foods, supports sustainable and personalized dietary approaches [7].

This review explores chronic low-grade inflammation's critical role linking obesity and metabolic diseases. Expanded adipose tissue, especially visceral fat, recruits immune cells and secretes pro-inflammatory cytokines, creating a systemic inflammatory state. This disrupts insulin signaling, impairs pancreatic beta-cell function, and promotes hepatic steatosis, driving type 2 diabetes and cardiovascular complications [8].

This practical review covers current and emerging pharmacotherapeutic agents for obesity management, focusing on mechanisms, efficacy, and safety. It discusses established drugs like GLP-1 receptor agonists, highlighting their role in weight loss and improving glycemic control and lipid levels. Guidance on individualized pharmacotherapies based on patient characteristics and comorbidities is emphasized [9].

This review explores the complex genetic landscape underpinning obesity and metabolic syndrome, bridging genes to personalized medicine. It discusses how genetic variations influence energy balance and insulin sensitivity. Advancements in genomics, including GWAS and next-generation sequencing, uncover novel determinants, paving the way for risk stratification and precision therapies tailored to an individual's genetic predisposition [10].

Description

Obesity and metabolic syndrome represent a significant public health challenge, underpinned by a complex interplay of physiological, genetic, and environmental factors. At the cellular and tissue level, dysfunctions in key metabolic organs are central to their pathogenesis. Skeletal muscle lipid metabolism, for instance, plays a critical role where the accumulation of intramyocellular lipids and their bioactive derivatives directly interferes with insulin signaling pathways, leading to impaired glucose uptake and utilization. This disruption is further influenced by factors such as mitochondrial dysfunction and altered fatty acid transport, highlighting the importance of muscle lipid homeostasis in metabolic health [2]. Similarly, adipose tissue dysfunction is a crucial driver of insulin resistance in obese individuals. When adipocytes become hypertrophic, they exhibit chronic inflammation and altered adipokine secretion, collectively contributing to systemic metabolic derangements. Understanding how dysfunctional fat expansion leads to insulin signaling defects in distant organs, like the liver and muscle, is key for developing targeted interventions for obesity-related complications [3]. A pervasive theme across these conditions is chronic low-grade inflammation, which acts as a key mediator linking obesity to various metabolic diseases. Specifically, expanded adipose tissue, particularly visceral fat, actively recruits immune cells and secretes pro-inflammatory cytokines. This creates a systemic inflammatory state that profoundly disrupts insulin signaling, impairs pancreatic beta-cell function, and promotes hepatic steatosis, ultimately fostering the development of type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular complications [8].

Beyond localized tissue dysfunctions, broader systemic influences significantly contribute to metabolic health. The gut microbiota, for example, exerts multifaceted roles in the development of obesity and metabolic syndrome [1]. Microbial dysbiosis profoundly affects nutrient absorption, energy metabolism, inflammation, and hormone signaling, all of which influence weight gain and insulin resistance. Exploring mechanisms like short-chain fatty acid production and bile acid metabolism offers insights into potential therapeutic targets, including dietary interventions, prebiotics, probiotics, and even fecal microbiota transplantation [1]. Furthermore, genetic predispositions lay the foundation for an individual's susceptibility. The genetic landscape underlying obesity and metabolic syndrome is complex, with both common and rare genetic variations influencing fundamental processes like energy balance, fat distribution, and insulin sensitivity. Advances in genomics, such as genome-wide association studies and next-generation sequencing, are instrumental in uncovering these genetic determinants, paving the way for improved risk stratification and the development of precision therapies [10]. Complementing genetics, epigenetic mechanisms also play a significant role. These involve dynamic changes like DNA methylation, histone modifications, and the action of non-coding RNAs, which regulate gene expression in metabolic tissues and impact adipogenesis, insulin sensitivity, and energy expenditure. Critically, environmental factors, including diet and lifestyle, can induce these epigenetic changes, thereby predisposing individuals to metabolic dysfunction and offering new avenues for therapeutic intervention [6].

Given the complex etiology, a diverse array of management and preventive strategies is crucial. Lifestyle modifications, such as incorporating regular exercise, are fundamental. Physical activity effectively improves body composition, enhances insulin sensitivity, optimizes lipid profiles, and reduces systemic inflammation. Both aerobic and resistance training offer distinct yet synergistic benefits in mitigating the adverse metabolic consequences of obesity, emphasizing the need for tailored exercise prescriptions as a core component of management plans [4]. Dietary patterns also significantly impact metabolic health. Reviews highlight the benefits of Mediterranean, DASH, and plant-based diets in improving insulin sensitivity, lipid profiles, and reducing inflammation. The consistent message underscores the importance of whole foods, fiber, and healthy fats, while cautioning against highly processed foods and excessive sugar. Adopting sustainable and personalized dietary approaches remains crucial for both preventing and managing obesity-related metabolic disorders [7].

For individuals requiring more intensive intervention, medical and surgical options are available. Pharmacotherapy for obesity management has seen continuous advancements, with current and emerging agents like GLP-1 receptor agonists demonstrating efficacy in promoting weight loss and improving metabolic parameters, including glycemic control and lipid levels. Selecting appropriate pharmacotherapies requires an individualized approach, considering patient characteristics and comorbidities, to ensure effective medical treatment [9]. Moreover, bariatric surgery offers a profound and sustained impact on metabolic health. This comprehensive intervention leads to significant weight loss, improved glycemic control, and often the resolution of comorbidities such as type 2 diabetes, hypertension, and dyslipidemia, frequently surpassing the effects of conventional medical management. The profound metabolic benefits are attributed to various mechanisms, including hormonal changes, gut microbiota modulation, and altered nutrient sensing, though potential challenges and nutritional considerations post-surgery must also be addressed [5].

Ultimately, understanding the intricate interplay between various physiological systems, genetic predispositions, epigenetic influences, and environmental factors is paramount. The diverse range of therapeutic strategies, from personalized dietary and exercise regimens to advanced pharmacotherapies and surgical interventions, underscores a holistic approach to combating obesity and metabolic syndrome. This integrated perspective is vital for developing effective, patient-centered interventions aimed at improving overall metabolic health.

Conclusion

The landscape of obesity and metabolic syndrome is defined by intricate biological factors and diverse management strategies. Research highlights the critical roles of gut microbiota dysbiosis in affecting nutrient absorption, energy metabolism, and inflammation, thereby influencing weight gain and insulin resistance. Relatedly, skeletal muscle lipid metabolism, particularly intramyocellular lipid accumulation, interferes with insulin signaling, impacting glucose utilization. Adipose tissue dysfunction, marked by hypertrophy and chronic inflammation, also significantly contributes to systemic metabolic derangements, disrupting insulin signaling in other organs. A key underlying mechanism across these conditions is chronic low-grade inflammation, often originating from expanded adipose tissue, which promotes insulin resistance, beta-cell dysfunction, and hepatic steatosis. Beyond these physiological mechanisms, genetic variations and epigenetic modifications are increasingly recognized for influencing energy balance and susceptibility to metabolic disorders. Environmental factors like diet and lifestyle can trigger these epigenetic changes, shaping individual metabolic health. Effective interventions span from lifestyle adjustments such as exercise, which improves body composition and insulin sensitivity, to adopting beneficial dietary patterns like Mediterranean or plant-based diets. Medical and surgical approaches, including pharmacotherapy with GLP-1 receptor agonists and bariatric surgery, offer significant, sustained improvements in weight loss and glycemic control. Understanding these multifaceted contributions, from microbial to genetic influences and the array of therapeutic options, is essential for comprehensive obesity management.

References

1. Ji-Hui K, Seung-Woo J, Soo-Min K (2023) .Arch Pharm Res 46:247-259.

   , ,

2. Ana CPND, Mariana RLRPB, Luiz CJ (2022) .Metabolism 126:154942.

   , ,

3. T. SKS, N. IMRN, K. PPDP (2021) .Front Endocrinol (Lausanne) 12:699479.

   , ,

4. Robert PG, Samuel DWG, William EE (2020) .Sports Med 50:19-33.

   , ,

5. Geltrude M, Francesco R, David EC (2023) .Lancet Diabetes Endocrinol 11:593-605.

   , ,

6. Muhammad AQ, Mohammad HQ, Mohammad SSAK (2022) .Genes Genomics 44:753-764.

   , ,

7. Konstantinos LK, Anastasia S, Aggeliki A (2023) .Nutrients 15:1526.

   , ,

8. Ana PNSdO, Patrícia TFEdS, Ana LVGeS (2021) .Eur J Clin Nutr 75:1-10.

   , ,

9. Caroline MA, W. SB, Robert FK (2024) .Mayo Clin Proc 99:107-124.

   , ,

10. T. JBKSB, S. BKNSDS, P. WBPAKW (2019) .Biomed Pharmacother 119:109405.

    , ,